Table 3. Patient characteristics for those who achieved stable disease of at least 6 months, partial response, or complete response.

Case #	Best Response %	Treatment duration (months)	KRAS mutation	PTEN	TP53 mutation	EGFR mutation	HER2 Amplification	PIK3CA mutation	Prior bevacizumab	Prior cetuximab	Prior panitumumab	Brain metastases	Dose Level	Rash Grade
135	−81	21	NO	ND	ND	ND	ND	ND	YES	NO	NO	NO	7	2
336	−44	6+	NO	ND	YES	NO	NO	NO	YES	NO	NO	NO	8	3
291	−33	4	NO	ND	ND	NO	ND	NO	YES	YES	NO	NO	8	2
171	−23	6	NO	ND	YES	NO	ND	NO	YES	YES	NO	NO	8	1
215	−20	6	NO	ND	ND	ND	ND	ND	YESa	YESa	NO	NO	8	2
245	−16	10	NO	PRESENT	ND	NO	ND	NO	YES	YES	NO	NO	8	3
314	−14	8+	NO	ND	ND	ND	ND	ND	YES	YES	NO	NO	8	2
335	−11	6+	NO	ND	ND	ND	ND	ND	YES	NO	YES	NO	8	1
235	−11	10	NO	LOSS	YES	ND	ND	NO	YES	YES	NO	NO	8	3
327	−9	7+	NO	ND	ND	NO	ND	ND	YES	NO	YES	NO	8	1
277	−9	6	NO	ND	ND	ND	ND	ND	YES	YES	NO	NO	8	2
260	−4	6	NO	PRESENT	ND	ND	ND	YES	YES	YES	NO	NO	8	2
221	0	6	ND	ND	ND	ND	ND	ND	YES	YES	NO	NO	8	3
22	10	6	ND	ND	ND	ND	ND	ND	YES	YES	NO	NO	2	0

Abbreviations: EGFR, epidermal growth factor receptor 1; HER2, human epidermal growth factor receptor 2; ND, not done; PIK3CA, phosphoinositide-3-kinase, catalytic, alpha polypeptide.

^aindicates patients who received prior study drugs concurrently.

⁺indicates ongoing therapy